1-8 of 8
Yiping Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Available to Purchase
Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, QiMing Wang, Yueyin Pan, Jianying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yunpeng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiuwei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luonan Chen, Caicun Zhou, Shengxiang Ren
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4830–4843.
https://doi.org/10.1158/1078-0432.CCR-23-0604
Published: 01 December 2023
View articletitled, HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
Open the PDF for HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models

Available to Purchase
Grace B. McKay-Corkum, Victor J. Collins, Choh Yeung, Takeshi Ito, Sameer H. Issaq, David Holland, Ksenia Vulikh, Yiping Zhang, Unsun Lee, Haiyan Lei, Arnulfo Mendoza, Jack F. Shern, Marielle E. Yohe, Kazutoshi Yamamoto, Kelli Wilson, Jiuping Ji, Baktiar O. Karim, Craig J. Thomas, Murali C. Krishna, Leonard M. Neckers, Christine M. Heske
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4479–4491.
https://doi.org/10.1158/1078-0432.CCR-23-0200
Published: 01 November 2023
View articletitled, Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Open the PDF for Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models in another window
Includes: Supplementary data
Journal Articles

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Open Access
Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jianying Zhou, Dong-Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi-Long Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1879–1886.
https://doi.org/10.1158/1078-0432.CCR-22-3318
Published: 15 May 2023
View articletitled, Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Open the PDF for Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis in another window
Includes: Supplementary data
Journal Articles

Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

Available to Purchase
Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, Chunwei Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, Shun Lu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 461–467.
https://doi.org/10.1158/1078-0432.CCR-21-2936
Published: 01 February 2022
View articletitled, Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Open the PDF for Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial in another window
Includes: Supplementary data
Journal Articles

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma

Free
Christine M. Heske, Mindy I. Davis, Joshua T. Baumgart, Kelli Wilson, Michael V. Gormally, Lu Chen, Xiaohu Zhang, Michele Ceribelli, Damien Y. Duveau, Rajarshi Guha, Marc Ferrer, Fernanda I. Arnaldez, Jiuping Ji, Huong-Lan Tran, Yiping Zhang, Arnulfo Mendoza, Lee J. Helman, Craig J. Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7301–7311.
https://doi.org/10.1158/1078-0432.CCR-17-1121
Published: 30 November 2017
View articletitled, Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
Open the PDF for Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

Free
Apurva K. Srivastava, Melinda G. Hollingshead, Jennifer Weiner, Tony Navas, Yvonne A. Evrard, Sonny A. Khin, Jiuping Jay Ji, Yiping Zhang, Suzanne Borgel, Thomas D. Pfister, Robert J. Kinders, Donald P. Bottaro, W. Marston Linehan, Joseph E. Tomaszewski, James H. Doroshow, Ralph E. Parchment
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (14): 3683–3694.
https://doi.org/10.1158/1078-0432.CCR-15-2323
Published: 14 July 2016
View articletitled, Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
Open the PDF for Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Free
Patricia M. LoRusso, Jing Li, Angelika Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Lawrence Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine Ferry-Galow, Robert J. Kinders, Ralph E. Parchment, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3227–3237.
https://doi.org/10.1158/1078-0432.CCR-15-0652
Published: 30 June 2016
View articletitled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Free
Shivaani Kummar, Jiuping Ji, Robert Morgan, Heinz-Josef Lenz, Shannon L. Puhalla, Chandra P. Belani, David R. Gandara, Deborah Allen, Brian Kiesel, Jan H. Beumer, Edward M. Newman, Larry Rubinstein, Alice Chen, Yiping Zhang, Lihua Wang, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1726–1734.
https://doi.org/10.1158/1078-0432.CCR-11-2821
Published: 14 March 2012
View articletitled, A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas in another window
Includes: Supplementary data